Valeant Pharmaceuticals Intl (NYSE:VRX)'s revenue slipped in the fourth quarter amid dropping drug prices
March 1, 2017
The Canadian drug giant Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) announced results of its fiscal fourth quarter as its revenue plunged 13% during the period, affected by the performance of the stomach-drug business it attempted to…